The estimated Net Worth of Vision Scs Jovan Embiricos ... is at least $27.3 Milion dollars as of 2 August 2022. Vision Embiricos owns over 49,910 units of Cullinan Oncology stock worth over $22,582,215 and over the last 3 years Vision sold CGEM stock worth over $4,756,726.
Vision has made over 2 trades of the Cullinan Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently Vision sold 49,910 units of CGEM stock worth $711,717 on 2 August 2022.
The largest trade Vision's ever made was selling 418,738 units of Cullinan Oncology stock on 12 May 2022 worth over $4,045,009. On average, Vision trades about 156,216 units every 27 days since 2022. As of 2 August 2022 Vision still owns at least 1,255,963 units of Cullinan Oncology stock.
You can see the complete history of Vision Embiricos stock trades at the bottom of the page.
Vision's mailing address filed with the SEC is 74 GRAND-RUEC/O LJ MANAGEMENT (SUISSE) SA, 8, RUE SAINT-LEGER, LUXEMBURGGENEVA, V8V8, L-1660CH-1205.
Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke a Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology executives and other stock owners filed with the SEC include: